Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03274687 · ClinicalTrials.gov registry record · Phase 3
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
A Phase 3 study, sponsored by NRG Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 296
- Enrollment target
NCT03274687 is a Phase 3 study that has completed, run by NRG Oncology. The registered enrollment target is 296 participants.
The verdict
NCT03274687, a Phase 3 study, has completed, sponsored by NRG Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 296 participants
- Enrollment target
Study Summary
This randomized phase III trial studies how well hypofractionated radiation therapy works compared to conventional radiation therapy after surgery in treating patients with prostate cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Conventional radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. It is not yet known whether giving hypofractionated radiation therapy or conventional radiation therapy after surgery may work better in treating patients with prostate cancer.
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- RADIATION Radiation Therapy
- RADIATION Hypofractionated Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 296 participants |
| Start Date | 2017-07-28 |
| Est. Completion | 2025-12-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03274687
The ClinicalTrials.gov registry entry for NCT03274687 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 296 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03274687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03274687 about?
NCT03274687 is a clinical study titled "Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer". This randomized phase III trial studies how well hypofractionated radiation therapy works compared to conventional radiation therapy after surgery in treating patients with prostate cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time an...
What is the current status of trial NCT03274687?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 296 participants. The study started on 2017-07-28. Estimated completion is 2025-12-23.
What interventions are being tested in trial NCT03274687?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Radiation Therapy (RADIATION), Hypofractionated Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT03274687?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.